Literature DB >> 34161617

Saroglitazar for the Treatment of NASH: The Peroxisome Proliferator-Activated Receptor Story Goes On!

Sven Francque1,2,3,4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 34161617     DOI： 10.1002/hep.32024

Source DB:  PubMed          Journal:  Hepatology        ISSN： 0270-9139            Impact factor:   17.425


× No keyword cloud information.
  2 in total

1.  Nonalcoholic Steatohepatitis, Peroxisome Proliferator-Activated Receptors and Our Good Glitazar: Proof of the Pudding is in the Eating.

Authors:  Anil C Anand; Subrata K Acharya
Journal:  J Clin Exp Hepatol       Date:  2022-01-25

2.  Rifaximin Ameliorates Non-alcoholic Steatohepatitis in Mice Through Regulating gut Microbiome-Related Bile Acids.

Authors:  Jie Jian; Mei-Tong Nie; Baoyu Xiang; Hui Qian; Chuan Yin; Xin Zhang; Menghui Zhang; Xuan Zhu; Wei-Fen Xie
Journal:  Front Pharmacol       Date:  2022-04-04       Impact factor: 5.988
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.